• News
  • SAN DIEGO
  • BioTech

Cadence reports strong sales for acetaminophen injection

San Diego-based Cadence Pharmaceuticals Inc. (Nasdaq: CADX) has announced a preliminary estimate of net product revenue from sales of its Ofirmev acetaminophen injection for the three months ended Dec. 31, 2012.

In a release Wednesday, the company said it ended 2012 on a high note, with fourth quarter revenues exceeding the guidance given in its announcement of our third quarter 2012 financial results. The company's unaudited net product revenue from Ofirmev for the fouth quarter was reported to be approximately $17.1 million.

Ted Schroeder, president and CEO of Cadence, said the company believes its strategy to increase access to Ofirmev within the hospital and to build awareness of the product has resulted in growing sales.

As of Jan. 23, Cadence expects that net product revenue from sales of Ofirmev for the 12 months ending Dec. 31, 2013, will range from approximately $94.0 million to $100.0 million.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Cadence Pharmaceuticals Inc.

Company Website

12481 High Bluff Dr. Ste., 200
San Diego, CA 92130

Cadence Pharmaceuticals Inc. Executive(s):

Theodore Schroeder

  • Chief Executive Officer, President

Related Articles